Neuronetics (NASDAQ:STIM) Posts Earnings Results, Misses Expectations By $0.08 EPS

Neuronetics (NASDAQ:STIM - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08), Zacks reports. Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%. The business had revenue of $31.98 million for the quarter, compared to the consensus estimate of $29.07 million. Neuronetics updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Neuronetics Trading Down 1.8 %

Shares of NASDAQ STIM traded down $0.09 during trading hours on Friday, hitting $4.57. The company's stock had a trading volume of 124,599 shares, compared to its average volume of 720,051. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16. Neuronetics has a 12 month low of $0.52 and a 12 month high of $5.92. The stock has a market cap of $300.45 million, a price-to-earnings ratio of -3.71 and a beta of 1.92. The business has a 50-day simple moving average of $4.27 and a 200-day simple moving average of $2.80.

Insider Activity at Neuronetics

In other news, EVP William Andrew Macan sold 12,175 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $46,630.25. Following the sale, the executive vice president now directly owns 388,647 shares of the company's stock, valued at $1,488,518.01. The trade was a 3.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Stephen Furlong sold 14,836 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $48,662.08. Following the transaction, the chief financial officer now directly owns 482,572 shares of the company's stock, valued at approximately $1,582,836.16. This trade represents a 2.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 100,369 shares of company stock worth $358,929 over the last quarter. 8.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group increased their price target on shares of Neuronetics from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.